Navigation Links
B-Cell Biologic Therapy Could Revolutionize Rheumatoid Arthritis Treatment

Biologic therapy directed at B-cells could turn out be more effective in the treatment of rheumatoid arthritis, a chronic inflammatory disease arising out of an auto immune disorder.//

An international study conducted on Rituximab, a form of biologic therapy for treatment of rheumatoid arthritis has been found to achieve remission in rheumatoid arthritis patients who exhibit resistance to conventional DMARDs. The effect, independent of steroid administration is seen despite the variability in the dosage of the drug.

Drugs aimed at suppressing inflammation-provoking cytokines--specifically those linked to T-cells--have improved the treatment of rheumatoid arthritis (RA). Still, the frequency of remission achieved by these biologic agents remains below 50 percent. To increase the success rate of biologic therapy for RA patients, researchers have honed in on a new target: the B cell.

Rituximab, a biologic agent that selectively depletes B cells, has been successfully used to treat non-Hodgkin's lymphoma. It has also been shown to improve disease symptoms for RA patients, when injected at aggressive levels for a two-week period. To investigate this biologic's potential long-term therapeutic value, an international team of scientists set out to compare the effectiveness and safety of different rituximab doses over a 24-week period, with and without steroids. Their study focused on 465 RA patients with moderate to severe symptoms resistant to disease-modifying antirheumatic drugs (DMARDs), including other biologics. The results, featured in the May 2006 issue of Arthritis & Rheumatism.

Drawn from outpatient populations in California, Texas, Arizona, Switzerland, Sweden, Poland, and England, the subjects were randomly divided into nine treatment groups. Three groups received a 1,000-mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a 50 0 mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a placebo with either intravenous steroid, oral steroid, or another placebo. All subjects received the DMARD methotrexate (MXT). All subjects were evaluated every four weeks for changes in the Disease Active Score (DAS), a 28-joint assessment for swelling and tenderness, as well as for overall disease improvement, with the goal of meeting the American College of Rheumatology (ACR) 20 percent improvement criteria.

At the 24-week culmination, 54 percent of the subjects in three rituximab 1,000 mg. X 2 groups and 55 percent of the subjects in the three rituximab 500 mg. X 2 groups had achieved the desired ACR20 response, compared with 28 percent of the subjects in the three placebo groups. The different dosages of rituximab did not have a statistically significant impact on the odds of achieving an ACR20 response, and analyses of the proportions of patients who achieved higher ACR improvement scores--50 percent and 70 percent--showed similar patterns. Changes in DAS28 at week 24 reflected the ACR response findings, as did the subjects reports of relief from joint pain and stiffness. What's more, subjects in the rituximab groups showed gains toward disease remission earlier in the course of treatment than subjects in the placebo group.

Steroids, whether received intravenously or orally, showed no significant correlation with disease improvement scores among the rituximab groups. Intravenous steroid, however, showed a positive correlation to improved tolerability during the first rituximab infusion in both dosage groups. Overall, adverse events associated with rituximab were mild and easily managed. Headache was the most common complaint.

Confirming the role of B cells in the inflammatory processes behind RA, this study demonstrates the effectiveness and safety of a unique biologic therapy, in moderat e doses and independent of steroids. Yet, as its leading author, Dr. Paul Emery, notes, further studies are needed before applying the results to the routine treatment of RA patients. 'Both doses of rituximab explored in this study warrant further differential exploration and longer-term follow-up,' he stresses.


'"/>




Related medicine news :

1. Smallpox as Biological Weapons?
2. Biologicals Transfer Proposal between US and Indian Biotechnology
3. Novel Biological Pacemaker Under Construction for Weak Hearts
4. Biologically Women Are More Vulnerable To HIV Infection
5. Biological Clock Could Be Re-Set: Study
6. Gold Nanoparticles Are Good Detectors Biological Toxins
7. Sunglasses Can Really Pull a Fast One on the Biological Clock, and Set a Lag in the Build Up Of Jet Lag
8. Can Men Gauge Biological Paternity Accurately
9. Biological Basis for Homosexuality
10. Biological Basis Behind a Couch Potato
11. Artificial Light May Damage Biological Clock In Premature Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and financial planning firm that serves residential and commercial clients in the greater ... drive to raise community support for the fight against cancer. , Founded by ...
(Date:8/18/2017)... ... 18, 2017 , ... With over 16,000 active patients, BodyLogicMD, ... therapy and integrative medicine, has become a frontrunner for people seeking help with ... andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by Patrick ...
(Date:8/18/2017)... ... August 18, 2017 , ... Inc. magazine has ranked American ... prestigious ranking of the nation's fastest-growing private companies. This marks the eighth time in ... 5000 ranking . This year’s ranking reflects ASH’s 76 percent overall revenue growth from ...
(Date:8/18/2017)... ... 2017 , ... “Dangerous Inheritance”: a mystery about saving the family farm. ... Southwest Nebraska where she was raised on a farm. As Diane wrote this ... but the friendships and mantra of ‘neighbors helping neighbors’ have always been a large ...
(Date:8/18/2017)... ... 18, 2017 , ... “Depressed: Super Heroes of the Bible”: a gripping ... stories and the relevance these tales may have on the reader’s life. “Depressed: Super ... special education teacher, Jessica spends much of her time enjoying nature and her family ...
Breaking Medicine News(10 mins):
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall ... to its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). ... UV disinfection robot that uses UVC light energy to kill deadly pathogens such as ... Tru-D ... Tru-D in action ...
(Date:8/2/2017)... Aug. 2, 2017 CaryRx, a next-generation full-service pharmacy, ... service for patients in the Washington D.C. ... pharmacy by providing delivery of medications through the convenience of ... delivery or delivered within one hour to any location in ... to bring this invaluable service to Washington D.C. ...
Breaking Medicine Technology: